12th Feb: Efficacy of AC102 for the Preservation of Residual Hearing following Cochlear Implantation


Dr. Michael Nieratschker from Allgemeines Krankenhaus Medical University of Vienna, Austria will present preclinical results performed in a model of electrode insertion trauma. This study was conducted in collaboration with MED-EL Medical Electronics, Austria and AudioCure Pharma, Germany.  Combining a range of electrophysiological, immunohistochemical and molecular biology techniques, the exciting work is the first to demonstrate AC102 as a promising candidate for the preservation of residual hearing following cochlear implantation.


14th Feb: AC102 – Phase I Results and Phase II Initiation for a New Drug Candidate for the Treatment of Sudden Sensorineural Hearing Loss


Dr Reimar Schlingensiepen, CEO of AudioCure Pharma GmbH, will present the results of a placebo-controlled Phase I clinical trial with AC102 in healthy volunteers conducted at Radboud University Medical Center (Radboudumc) in The Netherlands and Allgemeines Krankenhaus, Vienna. As this was a first-in-human study, a wide range of both audiological and otological assessments as well as biochemical and pharmacokinetic parameters were performed.

In this study, AC102 was well tolerated, allowing its application in patients in subsequent clinical trials. Consequently, AC102 is currently being evaluated in SSNHL patients in a Phase II clinical trial.


Contact AudioCure

AudioCure Pharma GmbH
Frauke Luers